SCHEMBL24323552

SCHEMBL24323552

O=C(NCC[C@H]1CCCCN1)C(=O)NC1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.51
RAB9A P51151 4/20 0.51
GAA P10253 1/20 0.51
NPC1 O15118 4/20 0.49
MAPT P10636 3/20 0.47
EPHX1 P07099 2/20 0.43
FDPS P14324 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP2D6 P10635 2/20 0.39
LMNA P02545 2/20 0.39
TP53 P04637 2/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 1/20 0.39
MLNR O43193 1/20 0.39
ABCB11 O95342 1/20 0.39
EGFR P00533 1/20 0.39
FYN P06241 1/20 0.39
CHRM2 P08172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24322789 0.97 SMN1; SMN2 (0.48) SMN1; SMN2RAB9AGAANPC1MAPT
SCHEMBL24323660 0.81 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AGAANPC1MAPT
SCHEMBL24323644 0.80 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AGAANPC1MAPT
SCHEMBL28747806 0.79 FDPS (0.45) SMN1; SMN2MAPTFDPSMEN1KMT2A
SCHEMBL27916091 0.78 FDPS (0.44) SMN1; SMN2MAPTFDPSMEN1KMT2A
SCHEMBL1038424 0.78 FDPS (0.44) SMN1; SMN2MAPTFDPSMEN1KMT2A
SCHEMBL24322395 0.78 FDPS (0.44) SMN1; SMN2MAPTFDPSMEN1KMT2A
SCHEMBL24322652 0.76 SMN1; SMN2 (0.42) SMN1; SMN2RAB9AGAANPC1MAPT
SCHEMBL24323854 0.76 NPC1 (0.60) SMN1; SMN2RAB9AGAANPC1EPHX1
SCHEMBL24322419 0.75 TDP1 (0.51) RAB9AGAAEPHX1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof Psomagen Inc. (US) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof HTRA1, GIPR, HPN SMN1; SMN2 4226/4885RAB9A 435/4885GAA 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.